Dr. Suresh Ramalingam is a longtime friend of mine and a national leader in the field of lung cancer.  He is the Director of the Lung Cancer Program at the Winship Cancer Institute at Emory University in Atlanta, and he was kind enough to sit down with me to talk about his perspective on the current optimal treatment for patients with stage III, or locally advanced, NSCLC.  We also spoke about managing metastatic disease, which will be covered in a separate podcast.  It’s an audio interview, but if people watch the video version, there are some figures synchronized with the discussion.

[display_podcast]

The transcript and figures associated with this program are included here:

Ramalingam Locally Advanced NSCLC Interview Transcript

Ramalingam Locally Advanced NSCLC Interview Figures

Talking with other lung cancer experts is a fun way to clarify what strategies are emerging as clear standards and what issues remain controversial.   Let me know if you have any suggestions about the format.

Podcast: Play in new window | Download

Related posts:

Balancing Risks of Undertreatment vs. Overtreatment of Locally Advanced NSCLC Our multidisciplinary thoracic oncology tumor board is dynamic and a highlight o...

Challenging Cases Podcast: Unresectable Stage IIIB NSCLC Here’s another case in the recording I did with Drs. Jyoti Patel from Northwester...

Challenging Cases in Lung Cancer: Stage IIIA N2 Node-Positive NSCLC, Debatably Resectable As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lun...

ASCO Highlights in Advanced NSCLC, by Dr. Nasser Hanna Here’s the second talk from our recent webinar, partnering with LUNGevit...

Do We Exhaust the Benefit of a Chemo After Four Cycles of First Line Chemo for Advanced NSCLC? One of the longstanding ideas in lung cancer management is that you exhaust the benefi...